



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
07/864,692	04/07/92	ISRAEL D	GI-5192

LEGAL AFFAIRS DEPARTMENT
GENETICS INSTITUTE, INC.
87 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140

EXAMINER	
ALLEN, M	
ART UNIT	PAPER NUMBER
1812	9

DATE MAILED: 01/25/93

Please find below a communication from the EXAMINER in charge of this application.

Serial No. 07/864,692

Commissioner of Patents

AU 1812

5 The communication filed on 9 November 1992 is not deemed to
be fully responsive to the Notice to Comply with Requirements for
Patent Applications Containing Nucleotide Sequence and/or Amino
10 Acid Sequence Disclosures mailed 7 October 1992 because of the
reason(s) set forth in the indicated paragraph(s) on the attached
form.

15 Since the response appears to be bona fide, but through an
apparent oversight or inadvertence failed to provide a complete
response, applicant is required to complete the response within a
time limit of one (1) month from the date of this letter or
within the time remaining in the response period of the Notice to
Comply, whichever is longer. (37 C.F.R. § 1.135(c).

20 NO EXTENSION OF THIS TIME LIMIT MAY BE GRANTED UNDER EITHER
37 C.F.R. § 1.136(a) OR (b) BUT THE PERIOD FOR RESPONSE SET IN
THE NOTICE TO COMPLY MAY BE EXTENDED UP TO A MAXIMUM OF SIX (6)
MONTHS UNDER EITHER 37 C.F.R. § 1.136(a) OR (b).

25 Any inquiry concerning this communication or earlier
communications from the examiner should be directed to Marianne
P. Allen whose telephone number is (703) 308-0666.

30 Any inquiry of a general nature or relating to the status of
this application should be directed to the Group receptionist
whose telephone number is (703) 308-0196.

Robert J. Hill, Jr.
ROBERT J. HILL, JR.
SUPERVISORY PATENT EXAMINER
GROUP 1800

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☐ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☒ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:

☐ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _____

☐ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.

☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____

☒ d. Other: *There are no sequence ID numbers or listing for sequences disclosed in Fig. on page 78, lines 1-9; on page 78 line 13; and page 79 lines 1-8. The amendment to page 41, line 3, has not been entered because there is no sequence on this line. It is believed that sequence ID 15 is found on page 41, line 23. Proper amendment is requested.*

☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).

☐ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).

☐ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: _____

☐ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).

☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).

☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____

☐ 11. Other: _____

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.

☐ For: Manager, Application Processing Division
(703) 308-1202 or 308- _____

☒ M.P. Allen
Examining Group 1812
(703) 308- 0666